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Background and Objectives: Glial scarring and inflammation after spinal cord injury (SCI) interfere with neural re-
generation and functional recovery due to the inhibitory microenvironment of the injured spinal cord. Stem cell trans-
plantation can improve functional recovery in experimental models of SCI, but many obstacles to clinical application 
remain due to concerns regarding the effectiveness and safety of stem cell transplantation for SCI patients. In this 
study, we investigated the effects of transplantation of human mesenchymal stem cells (hMSCs) that were genetically 
modified to express Olig2 in a rat model of SCI.
Methods: Bone marrow-derived hMSCs were genetically modified to express Olig2 and transplanted one week after 
the induction of contusive SCI in a rat model. Spinal cords were harvested 7 weeks after transplantation.
Results: Transplantation of Olig2-expressing hMSCs significantly improved functional recovery in a rat model of con-
tusive SCI model compared to the control hMSC-transplanted group. Transplantation of Olig2-expressing hMSCs also 
attenuated glial scar formation in spinal cord lesions. Immunohistochemical analysis showed that transplanted 
Olig2-expressing hMSCs were partially differentiated into Olig1-positive oligodendrocyte-like cells in spinal cords. 
Furthermore, NF-M-positive axons were more abundant in the Olig2-expressing hMSC-transplanted group than in the 
control hMSC-transplanted group. 
Conclusions: We suggest that Olig2-expressing hMSCs are a safe and optimal cell source for treating SCI.
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Introduction 
  Recovery from spinal cord injury (SCI) is more difficult 
than from peripheral nerve damage, often leaving patients 
with permanent disabilities. SCIs can be time-consuming, 
psychologically and economically damaging disasters. The 
major causes of disability due to SCI involve loss of motor, 
sensory and autonomic nerves below the site of upper spi-
nal injury. The severity of damage is classified as either 
complete or partial loss of function (1, 2). The severity of 
SCIs is determined not only by the primary cause but also 
by secondary processes such as ischemia, anoxia, free radi-
cal formation, and excitotoxicity that occur in the next few 
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hours or days following injury (3). Several animal models 
have been used to refine clinical approaches to treat SCI 
and are categorized into two major groups based on the 
method of injury, transection models and contusion 
models. The contusion model is considered more clinically 
relevant than the transection model because SCI in the 
majority of patients is usually contusive (4). However, 
complete functional recovery from SCI is still not possible 
with current therapeutic approaches.
  Transplantation of stem cells in rodent models of SCI 
has been shown to induce axonal growth, replace neuronal 
populations lost by injury, and improve functional recov-
ery (reviewed in 5, 6). Human mesenchymal stem cells 
(hMSCs) derived from bone marrow are capable of self-re-
newing in vitro. These multipotent stem cells can differ-
entiate into a variety of mesodermal cells (7, 8). Several 
research groups, including ours, have reported that 
hMSCs may also transdifferentiate into neuron-like cells 
that have neural cell markers and similar functional activ-
ity to that of neural cells (9-13). Manipulation of specific 
factors can accelerate transdifferentiation of hMSCs into 
neuron-like cells (14).
  Oligodendrocyte lineage transcription factor 2 (Olig2) 
is, as a basic helix-loop-helix transcription factor, an es-
sential regulatory factor for the differentiation of motor 
neurons and oligodendrocytes in the developing central 
nervous system (15, 16). Recent studies have demonstrated 
that Olig2 expression not only promotes neural stem cell 
differentiation into mature oligodendrocytes, but also im-
proves locomotor recovery in rat spinal cord following 
contusive injury (17, 18). In this study, we genetically 
modified hMSCs to express Olig2 and investigated the ef-
fects of transplantation of Olig2-expressing hMSCs in a 
contusion model of rat spinal cord injury. Cells were 
transplanted in animals at 7 days after SCI, and behav-
ioral outcomes and histological changes were evaluated 8 
weeks after SCI.
Materials and Methods
Human mesenchymal stem cell culture
  Cryopreserved adult hMSCs (Poietics® normal human 
mesenchymal stem cells) were purchased from Cambrex 
Bio Science Walkersville (Walkersville, MD, USA). We 
cultured hMSCs (passages 4-12) in Dulbecco’s modified 
Eagle’s medium (DMEM)-low glucose (Hyclone) contain-
ing 10% fetal bovine serum (FBS; Gibco-BRL) at 37oC 
with 5% CO2.
Lentiviral vector construction and virus production
  The lentiviral vector for expressing the mouse Olig2 
gene was constructed by inserting the EcoR I – EcoR V 
gene fragment into the EcoR I – pme I site of the 
LentiM1.41 vector. The LentiM1.41 lentiviral vector was 
designed to produce interesting gene promotion from the 
murine cytomegalovirus (mCMV) promoter and to express 
eGFP from the PGK promoter. The nucleotide sequences 
of the constructs were verified by sequencing. 
  Macrogen, Inc. produced pseudotyped lentiviruses as 
described previously (19, 20). Briefly, three plasmids, a 
transfer vector, a VSV-G expression vector, and a gag-pol 
expression vector, were co-transfected into HEK-293T 
cells at a 1:1:1 molar ratio using Lipofectamine Plus 
(Invitrogen). The culture supernatant containing viral vec-
tor particles was harvested 48 hours later, clarified with 
a 0.45-μm membrane filter (Nalgene), concentrated using 
a Centricon Plus-20 (Millipore) and immediately stored at 
−70oC in a deep-freezer. Titers were determined by p24 
ELISA and infection into HeLa cells. The eGFP ex-
pression of transduced cells was observed and photo-
graphed under a fluorescence microscope. The titer was 
approximately 106∼107 transduction units (TU) per mL 
without further concentration. 
Lentiviral transduction
  All plasmid constructs were introduced into hMSCs by 
viral infection. The cells (2.4×104 cells/well) were plated 
in six-well plates 2 days before transduction. hMSCs were 
infected with lentiviral vectors in the presence of 8 μg/mL 
polybrene. After 6 hours, the media were replaced with 
fresh growth media. Two days after viral infection, cells 
were selected using 1 μg/mL puromycin for 7 days. 
Immunocytochemistry
  Cells were fixed on coverslips with 4% paraformalde-
hyde at room temperature for 30 minutes and per-
meabilized for 10 minutes with 0.2% Triton X-100 and 1% 
bovine serum albumin (BSA) in PBS. Blocking was per-
formed by incubating cells for 1 hour with 5% normal 
goat serum in PBS. Cells were then incubated overnight 
at 4oC with rabbit polyclonal anti-Olig2, 1:5,000 (gift from 
Dr. C. Stiles, Harvard Medical School). After washing 
with PBS, cells were incubated with goat anti-rabbit con-
jugated with Alexa Fluor 546, 1:500 (Invitrogen). All cells 
were mounted with fluorescent mounting medium (Dako). 
Immunofluorescence was examined using a laser-scanning 
confocal microscope (Fluoview FV300, Olympus).
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Fig. 1. Survival and distribution of Olig2-GFP-hMSCs in spinal cord lesion after contusive SCI. (A) Green fluorescent protein (GFP) and 
Olig2 expression in genetically modified hMSCs. The GFP-infected (GFP-hMSCs) and Olig2-GFP-infected (Olig2-GFP-hMSCs) hMSCs were 
immunostained with an anti-Olig2 (red) antibody. Colocalization of Oilg2 and GFP in the nucleus of Olig2-GFP-hMSCs is shown in the 
merged image (yellow). Scale bars: 100 μm. (B) Schematic diagram of the experimental design. (C) Immunohistochemistry of transplanted 
hMSCs in spinal cord lesion at 7 weeks after transplantation. Longitudinal spinal cord sections were immunostained for GFP at 7 weeks 
after transplantation of GFP-hMSCs and Olig2-GFP-hMSCs. Scale bars: 500 µm. The left side is rostral and the superior side is dorsal. 
Spinal cord contusion injury
  Adult male Sprague-Dawley rats (Daehan Biolink, 
Chungbuk, Korea) weighing 260∼280 g at the time of sur-
gery were housed in groups of four and allowed free access 
to food and water. All animal procedures were carried out 
under the approval of the Institutional Animal Care and 
Use Committee of Seoul National University. Acute SCI 
was induced with an NYU Impactor. The rats were anes-
thetized by intraperitoneal injections of Zoletil (35 mg/kg) 
and Rompun (2 mg/kg) and a laminectomy was performed 
at the level of T9. The exposed dorsal surface of the spinal 
cord in each rat was then subjected to a weight-drop 
impact. To obtain moderately contused SCI models, a 10-g 
weight–impact rod was dropped from a 25-mm height. 
The contusion impact velocity and compression rate were 
monitored to guarantee consistency of injury between ex-
perimental animals. During recovery, the rats’ rectal tem-
peratures were maintained at 37oC using a feedback- regu-
lated heating pad. Postoperative nursing care included 
bladder expression twice per day. Gentamicin sulfate (1 
mg/kg) was administered prophylactically to all animals 
for a week after SCI.
Behavioral assessment after spinal cord injury
  Open-field testing procedures, also known as Basso–
Beattie–Bresnahan (BBB) procedures (21), were used to 
measure the functional recovery of rat hindlimbs. The 
scale used to measure hindlimb function with these proce-
dures ranges from a score of 0, indicating no spontaneous 
movement, to a maximum score of 21, with an increasing 
score indicating the use of individual joints, coordinated 
joint movement, coordinated limb movement, weight-bear-
ing and other functions. Rats were first gently adapted to 
the open field used for the test. After each rat had walked 
continuously in the open field, two investigators con-
ducted 5-minute testing sessions on each leg. The 
open-field test was performed at least once per week from 
day 1 after SCI to 9 weeks after laminectomy on all ani-
mals in the study. 
Cell transplantation
  After rats had been subjected to behavioral tests for 1 
week, they were randomly allocated into groups that re-
ceived cell-culture medium, GFP-expressing hMSC trans-
plants, or Olig2-GFP-expressing hMSC transplants. At 7 
days after SCI, the rats were anesthetized by intra-
peritoneal injections of Zoletil (35 mg/kg) and Rompun 
(2 mg/kg), and received either 5 μL of GFP-hMSCs 
(1×105/μL) or Olig2-GFP-hMSCs (1×105/μL) trans-
planted through a capillary glass tube into the epicenter 
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Fig. 2. Behavioral analysis of loco-
motor function. Effect of trans-
plantation of Olig2-GFP-hMSCs on 
functional recovery after SCI. BBB 
locomotor scores of rats with SCI be-
fore and after transplantation of ve-
hicle (n=5), GFP-hMSCs (n=5) and 
Olig2-GFP-hMSCs (n=6) were anal-
yzed. Arrow indicates the time point 
when transplantation was performed.
Data are shown as mean±SEM. *p
＜0.05 vs. vehicle transplant group, 
†p＜0.05 vs. GFP-hMSC transplant 
group.
of the injury, or received a 5-μL injection of culture me-
dium into the epicenter of the injury (control). To induce 
immunosuppression, cyclosporine A (1 mg/100 g) was in-
jected daily from 2 days before injury until the day of 
transplantation or injection of culture medium. 
Histological processing and immunohistochemistry
  At 8 weeks after the induction of SCI, all rats were sac-
rificed by perfusion with 4% paraformaldehyde in phos-
phate-buffered saline (PBS) under anesthesia. The spinal 
cords were removed and fixed for 18 hours in 4% paraf-
ormaldehyde, followed by overnight immersion in 30% su-
crose in PBS. Serial longitudinal 12-μm-thick sections of 
the spinal cord were obtained with a cryostat. The speci-
mens were stored at −80oC before further processing. 
Staining with hematoxylin and eosin (H&E) was per-
formed for histopathological analysis.
  For immunohistochemical analysis, the spinal cord sec-
tions were rinsed with PBS for 3 minutes and fixed for 
30 minutes with 4% paraformaldehyde. The sections were 
then treated with blocking solution to prevent nonspecific 
staining and were incubated with anti-neurofilament-M 
(1:5,000; rabbit polyclonal; Chemicon), anti-glial fibrillary 
acidic protein (GFAP) (1:1,000; mouse monoclonal; 
Chemicon), anti-Iba1 (1:1,000; rabbit polyclonal; Wako), 
anti-Olig1 (1:20,000; rabbit polyclonal; kindly provided by 
Dr. C. Stiles, Harvard Medical School). After washing 
with PBS, the spinal cord sections were incubated with the 
following secondary antibodies: Alexa Fluor 488 an-
ti-mouse IgG (Invitrogen) and Alexa Fluor 546 anti-rabbit 
IgG (Invitrogen). The sections were mounted on glass 
slides with a fluorescent mounting medium (Vectashield; 
Vector Laboratories) and observed under a laser-scanning 
confocal microscope (Fluoview FV300, Olympus).
Histological analysis of tissue injury
  Histological analysis was carried out on 12-μm-thick 
longitudinal sections of spinal cord obtained from culture 
medium (n=5), GFP-hMSCs (n=5), or Olig2-GFP-hMSCs 
(n=6) transplanted rats that were stained with H&E. 
Lesioned areas were outlined using Image Pro software 
and lesion sizes were calculated for statistical analysis. 
Serial sections were also immunohistochemically proc-
essed for each marker protein. 
Statistical analysis
  Data were analyzed by two-tailed Student’s t-test or 
one-way analysis of variance (ANOVA) followed by post 
hoc comparisons with Fisher’s protected least significant 
difference (PLSD) test. A probability value of ＜0.05 was 
considered statistically significant. All values were ex-
pressed as the mean±standard error of the mean (SEM).
Results
Spinal cord injury and cell transplantation 
  In this study, we ectopically expressed Olig2 in hMSCs 
using Olig2-GFP-containing lentiviral vectors (Olig2-GFP- 
hMSCs). Control hMSCs were infected with GFP-contain-
ing lentiviral vectors (GFP-hMSCs). Both GFP-hMSCs 
and Olig2-GFP-hMSCs expressed green fluorescence un-
der a fluorescence microscope (Fig. 1A). Immunostaining 
for Olig2 demonstrated that Olig2-GFP-hMSCs ectopically 
expressed Olig2, whereas GFP-hMSCs did not. No sig-
nificant differences in morphology or viability were ob-
served between these cells. We next sought to determine 
survival and distribution of GFP-hMSCs and Olig2-GFP- 
hMSCs in spinal cord lesions at 7 weeks after trans-
plantation. Contusion injuries of the rat thoracic spinal 
cord was performed according to a standard protocol (21). 
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Fig. 3. Morphometry of spinal cord lesion after contusion SCI. Longitudinal spinal cord sections from the vehicle transplant group (A), 
GFP-hMSC transplant group (B), and Olig2-GFP-hMSC transplant group (C) were stained with hematoxylin and eosin (H&E) at 8 weeks 
after SCI. Histological analyses were conducted of longitudinal sections encompassing the lesion area. Dotted line outlines the lesion 
boundary. (D) The histograms represent measurements of the lesion area of vehicle transplant group, GFP-hMSC transplant group and 
Olig2-GFP-hMSC transplant group. (E) Correlations between BBB score 7 weeks post-injury and lesion size in the spinal cord tissue. Data 
are shown as mean±SEM. The results are representative of at least three rats in each group. *p＜0.05 vs. vehicle transplant group, †p＜0.05 
vs. GFP-hMSC transplant group.
At 7 days after SCI, animals received transplantation of 
GFP-hMSCs or Olig2-GFP-hMSCs (Fig. 1B). Transplant-
ed GFP-hMSCs and Olig2-GFP-hMSCs were found by 
GFP immunohistochemistry in the spinal cord lesion at 
7 weeks after cell transplantation (Fig. 1C), indicating sur-
vival of engrafted cells. 
Behavioral analysis of locomotor function 
  After the induction of SCI, all experimental rats showed 
flaccid paralysis of hindlimbs during the first few days af-
ter surgery. To determine the effect of Olig2-GFP-hMSC 
transplantation on functional recovery in contusion SCI 
rats, BBB scores were evaluated one day after injury. As 
shown in Fig. 2, one week after SCI (the day before hMSC 
transplantation), all rats received a score of 5 or less. 
There were no significant differences among the three 
groups. At the second week post-treatment, animals trans-
planted with Olig2-GFP-hMSCs showed significantly fast-
er functional recovery. From 3 to 7 weeks following treat-
ment, rats transplanted with Olig2-GFP-hMSCs showed 
significant increases in BBB scores compared to rats trans-
planted with GFP-hMSCs or sham-injected with culture 
medium (vehicle). At 6 and 7 weeks following treatment, 
the BBB scores of rats transplanted with GFP-hMSCs 
were greater than those of sham-injected rats. These re-
sults indicate that rats receiving transplantation of Olig2- 
GFP-hMSCs exhibited significantly enhanced functional 
recovery compared to rats transplanted with GFP-hMSCs 
or sham-injected with vehicle. 
Histological analysis
  To elucidate the mechanisms of enhanced locomotor re-
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Fig. 4. Olig1 immunohistochemistry of the spinal cord lesion at 7 weeks after transplantation. Longitudinal spinal cord sections were im-
munostained for Olig1 and GFP 7 weeks after transplantation of vehicle (A), GFP-hMSCs (B) and Olig2-GFP-hMSCs (C). The right panel 
is magnified images of the boxed area. White arrows show colocalization of Olig1 to GFP-positive cells. Scale bars: 500 μm. In all images, 
the left side is rostral and the superior side is dorsal. 
covery in rats transplanted with Olig2-GFP-hMSCs, we 
performed morphological analysis of spinal cord lesions 
using H&E staining. H&E staining showed that various 
cavity morphologies were formed at the spinal cord lesions 
of all SCI animals, including those that received trans-
plantations of GFP-hMSCs or Olig2-GFP-hMSCs as well 
as vehicle (Fig. 3A-C). The spinal cord cavity was largest 
in the vehicle transplant group. The spinal cord cavity of 
the GFP-hMSC transplant group and the Olig2-GFP- 
hMSC transplant group was smaller than that of the ve-
hicle transplant group. H&E stained images were man-
ually outlined and analyzed to quantify cavity area (Fig. 
3A-C). Cavity size in the Olig2-GFP-hMSC transplant 
group (1.18±0.06 mm2) was significantly reduced com-
pared to the GFP-hMSC transplant group (1.46±0.09 
mm2) as well as the vehicle transplant group (2.57±0.37 
mm2) (p＜0.05, Fig. 3D). These results indicate that 
Olig2-GFP-hMSCs attenuate glial scar formation in spinal 
cord lesions. Correlation analysis showed a significant cor-
relation (r=−0.967, p＜0.01) between the BBB score at 7 
weeks post-spinal cord injury and the size of the spinal 
cord injury site (Fig. 3E). 
Immunohistochemical analysis
  At 7 weeks after SCI, we performed immunohistochem-
ical analysis in longitudinal sections of injured spinal cord 
for all three treatment groups: vehicle transplantation, 
GFP-hMSC transplantation, and Olig2-GFP-hMSC trans-
plantation. Oligodendroglial lineage-associated marker 
Olig1 immunohistochemistry showed that expression of 
GFP and Olig1 was higher in the Olig2-GFP-hMSC trans-
plant group compared to the GFP-hMSC transplant group 
(Fig. 4). This suggests that transplanted Olig2-GFP- 
hMSCs partially differentiated into Olig1-positive oligo-
dendrocyte-like cells in spinal cords. Next, we investigated 
the expression of NF-M in transplanted GFP-hMSCs and 
host cells in the injured spinal cord. Transplanted 
Olig2-GFP-hMSCs, but not GFP-hMSCs, seemed to be di-
rectly associated with NF-M positive axons (Fig. 5). 
Furthermore, NF-M positive axons were more abundant 
in the Olig2-GFP-hMSC transplant group than in the 
GFP-hMSC transplant group. As expected, there were few 
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Fig. 5. NF-M immunohistochemistry of the spinal cord lesion at 7 weeks after transplantation. Longitudinal spinal cord sections were im-
munostained for NF-M and GFP 7 weeks after transplantation of vehicle (A), GFP-hMSCs (B), and Olig2-GFP-hMSCs (C). The right panel 
shows magnified images of the boxed area. White arrows show colocalization of NF-M to GFP-positive cells. Scale bars: 500 μm. In all
images, the left side is rostral and the superior side is dorsal. 
NF-M positive axons in the epicenters of injured spinal 
cords in the vehicle transplant group. Microglial marker 
Iba1 immunohistochemistry revealed increased density of 
Iba1-positive microglial cells in the host tissue of the ve-
hicle transplant group when compared to the Olig2-GFP- 
hMSC transplant or GFP-hMSC transplant groups (Fig. 
6). Next, we investigated the expression of astrocyte mark-
er GFAP in transplanted hMSCs and host cells at the in-
jured spinal cord. Quite a few cells expressed both GFP 
and GFAP in the spinal cord in the Olig2-GFP-hMSC 
transplant group (Fig. 7). This suggests that transplanted 
Olig2-GFP-hMSCs partially differentiated into Olig2- lin-
eage astrocytes (22).
Discussion
  In the present study, we demonstrate that the trans-
plantation of hMSCs that are genetically modified to ex-
press Olig2 enhances locomotor function in a rat model 
of contusive SCI model. Previous studies showed that 
transplants of bone marrow-derived MSCs have ther-
apeutic effects in SCI (23-26). Indeed, in the present 
study, transplantation of control hMSCs reduces cavity 
area in the injured spinal cord and leads to functional im-
provements in SCI. Although various types of stem cells 
have been used for the treatment of SCI, MSC trans-
plantation has several advantages (27, 28): MSCs are read-
ily available from donors and can be expanded and trans-
planted autologously. MSCs are at very low risk for malig-
nant transformation. In addition, autologous transplan-
tation of MSCs is known to have immunosuppressive 
properties. The safety of MSCs has been demonstrated in 
several clinical studies (29, 30). However, it is necessary 
to optimize therapeutic applications to treat SCI using 
MSC transplantation in clinical practice. The present 
study indicated that transplantation of hMSCs genetically 
modified to express Olig2 enhances locomotor function 
more significantly than control hMSCs in a rat model of 
contusive SCI model. 
  Several in vivo models of SCI have been widely used to 
study chronic pathologies after damage to spinal nerves 
(31, 32). In spinal cord tissues adjacent to the injured 
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Fig. 6. Iba1 immunohistochemistry of the spinal cord lesion 7 weeks after transplantation. Longitudinal spinal cord sections were im-
munostained for Iba1 and GFP 7 weeks after transplantation of vehicle (A), GFP-hMSCs (B), and Olig2-GFP-hMSCs (C). The right panel 
shows magnified images of the boxed area. Scale bars: 500 µm. In all images, the left side is rostral and the superior side is dorsal. 
area, direct injury and tissue disruption is alleviated as 
it moves away from the area of injury (33). SCI is asso-
ciated with loss of neurons and glia as well as many 
changes in gene expression and protein levels, leading to 
demyelination (34). In this study, Olig2 expression en-
hanced the therapeutic effects of hMSCs to improve func-
tional recovery after SCI, possibly by modulating the 
microenvironment. This effect may be due to the pro-
duction of growth factors and neurotrophic factors that 
regulate neuronal development, cell survival, and neurito-
genesis, but further studies are required to elucidate the 
precise mechanisms involved. Olig2 is highly expressed in 
the ventral spine during the early stages of human devel-
opment and plays an important role in oligodendrocyte 
differentiation of the spine (35). We found that Olig1- 
positive cells were the most abundant in injured spinal 
cord after transplantation of Olig2-GFP-hMSCs. In addi-
tion, some transplanted Olig2-GFP-hMSCs expressed 
Olig1 in the injured spinal cord, whereas control GFP- 
hMSCs did not. Our results suggest that hMSCs that are 
genetically modified to express Olig2 can transdiffer-
entiate into oligodendrocyte-like cells in the spinal cord, 
results that are supported by those of a previous study 
(36).
  Collectively, our results suggest that the transplantation 
of Olig2-expressing hMSCs has the potential to improve 
functional recovery of injured spinal cord. BBB scores re-
vealed that the transplantation of Olig2-expressing hMSCs 
resulted in greater functional improvement in SCI com-
pared that observed in a control hMSC transplant group. 
Treatment using hMSCs that are genetically modified to 
express Olig2 is thus considered to be a safe and optimal 
therapy for SCI. 
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Fig. 7. GFAP immunohistochemistry of the spinal cord lesion at 7 weeks after transplantation. Longitudinal spinal cord sections were im-
munostained for GFAP and GFP 7 weeks after transplantation of vehicle (A), GFP-hMSCs (B), and Olig2-GFP-hMSCs (C). The right panel 
shows magnified images of the boxed area. White arrows show colocalization of GFAP to GFP-positive cells. Scale bars: 500 µm. In all 
images, the left side is rostral and the superior side is dorsal. 
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